Clin2
NCT07473726Worth exploringRecruiting

Study of a new drug for advanced solid tumors

Advanced/Metastatic Solid Tumors

Part of Cancer clinical trials.

This trial tests an investigational drug (HLX48) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and how well it works.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
72 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You must be 18 to 75 years old.
  • You must have an advanced or metastatic solid tumor that has not responded to or is not eligible for standard treatments.
  • You must have at least one measurable tumor on a scan within the last 4 weeks.
  • You must be in fairly good physical condition (able to do light activity, like walking).
  • You must be willing to provide a tumor tissue sample from a past biopsy or have a new biopsy taken.
  • You must have no history of other cancers in the last 2 years, except for some early-stage cancers like cured skin cancer.
  • You must not have serious eye diseases, lung inflammation, or uncontrolled heart problems.
  • You must not be pregnant or breastfeeding, and you must use effective birth control during and for 6 months after treatment.
  • You must not have active infections like hepatitis B, C, or HIV.
  • You must not have had major surgery or certain other treatments within the past 4 weeks before starting the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07274813Recruiting· Early Phase 1
Study of HLX37 for advanced solid tumors that haven't responded to treatment

This early-phase study tests a new drug called HLX37 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it is safe and how it works in the body.

Shanghai
NCT07541534Recruiting· Phase 1
HLX316 immunotherapy for advanced solid tumors

This trial tests a new experimental drug called HLX316 in people with advanced or metastatic (spread) solid cancers that have not responded to standard treatments. The drug is designed to help your immune system fight cancer cells.

Chongqing
NCT07480681Not yet recruiting· Phase 1
Testing a new pill for advanced breast, prostate, and lung cancers

This trial tests a new daily pill called HLX97 for people with advanced cancers that have stopped responding to standard treatments. It may help if you have a type of breast cancer that is hormone-receptor positive and HER2-negative, or castration-resistant prostate cancer, or non-small cell lung cancer.

NCT06649708Recruiting· Phase 1/Phase 2
Study of HX044 for advanced solid tumors

This trial tests an experimental drug called HX044 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and helps shrink tumors.

Blacktown, New South Wales
NCT06115642Enrolling by invitation· Phase 1
Study of HLX43 for advanced solid tumors

This trial tests a new drug called HLX43 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It aims to find safe dosing and understand how the drug works in the body.

Stanford, California
NCT06210815Recruiting· Phase 1
Testing a new drug HLX42 for advanced solid tumors

This trial tests a new drug called HLX42 for people with advanced solid tumors (including a type of lung cancer called NSCLC) who have no good treatment options left. The goal is to see if it's safe and if it can help shrink tumors.

Guangdong, Guangzhou

Hear when a new Advanced/Metastatic Solid Tumors trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.